Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: alternative splicing therapeutics - Sarepta Therapeutics

Drug Profile

Research programme: alternative splicing therapeutics - Sarepta Therapeutics

Alternative Names: AVI-5038; DMD EXON 35; DMD EXON 43; DMD EXON 44; DMD EXON 50; DMD EXON 52; DMD EXON 55; DMD EXON 8; SRP 4044; SRP 4050; SRP 4052; SRP 4055; SRP 5044; SRP 5045; SRP 5050; SRP 5052; SRP 5053; SRP-4008

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Western Australia
  • Developer Ercole Biotech; Murdoch University; Sarepta Therapeutics
  • Class Antisense oligonucleotides; Morpholines
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Duchenne muscular dystrophy; Multiple sclerosis
  • Discontinued Thalassaemia

Most Recent Events

  • 28 May 2022 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (Parenteral)
  • 22 Jun 2020 Sarepta Therapeutics signs global research and option agreement with Codiak BioSciences to develop engineered exosome therapeutics
  • 04 May 2020 Preclinical development is ongoing in USA (Sarepta Therapeutics pipeline, May 2020)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top